Tag Archives: AGS-004

January, 2015

  • 9 January

    Argos’ Experimental HIV Immunotherapy Fails Phase 2 Study

    Argos Therapeutics Inc.’s experimental HIV immunotherapy failed its mid-stage trial. The company announced today that its investigational fully personalized immunotherapy, AGS-004, failed to meet the primary endpoint in its Phase 2b clinical trial, evaluating the drug in patients chronically infected with HIV-1. According to top-line results, AGS-004 did not meet …